BioMarin Official Calls Drisapersen AdCom ‘Critical Thinking On Display’
Executive Summary
CMO says advisory committee was tough on proposed Duchenne muscular dystrophy treatment in part because it was first to reach that stage.
You may also be interested in...
Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.
Harmonizing COVID Vaccine Schedule Good Idea, But US FDA Should Remain Flexible, Advisors Say
Vaccines and Related Biological Products Advisory Committee also said that more data is needed to determine the groups that potentially could receive more than one periodic vaccine booster.
US FDA Still Not Scheduling In-Person Meetings Despite Sponsor Requests
Some sponsors appear to be growing antsy to meet with agency staff and advisory committees in-person, but CDER continues to schedule only virtual meetings.